ArticleFrontiers in psychiatry2026
Longitudinal cardiometabolic trajectories in children and adolescents in therapy with second-generation antipsychotics: a real-world multicenter study.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Second-generation antipsychotics (SGAs) are widely utilized as first-line agents for several pediatric psychiatric and neurodevelopmental conditions, raising critical safety concerns. Although their cardiometabolic risks are well recognized, evidence on their long-term evolution in routine pediatric clinical practice remains limited. This study investigated the longitudinal cardiometabolic trajectories associated with SGA treatment in a real-world pediatric population. Methods: In this prospective, naturalistic, multicenter observational study, 82 children and adolescents initiating SGA treatment were followed for up to 24 months. Anthropometric, metabolic, and cardiovascular parameters were assessed longitudinally, and linear mixed-effects models were used to evaluate time-dependent changes and differences between treatment groups. Results: Retention rates and a low incidence of adverse event-related discontinuations suggested acceptable overall tolerability. Longitudinal analysis revealed significant increases in BMI, insulin and HOMA-IR whereas aggregate cardiovascular parameters did not exhibit statistically significant changes. Risperidone was associated with greater increases in waist circumference, prolactin, total cholesterol and ALT levels compared with aripiprazole. Furthermore, patients with Autism (ASD) exhibited significantly greater increases in BMI, waist circumference, and systolic blood pressure compared to non-ASD youth. Conclusion: While demonstrating an acceptable tolerability profile, risperidone and aripiprazole were associated with different cardiometabolic and endocrine variations over a 24-month period in this real-world pediatric cohort. These findings should be interpreted within the context of the study's observational nature and of potential confounding factors (e.g., unmeasured dietary, physical activity, and pubertal factors), highlighting the clinical necessity of longitudinal monitoring in children and adolescent patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.